Skip to Main Content
It looks like you're using Internet Explorer 11 or older. This website works best with modern browsers such as the latest versions of Chrome, Firefox, Safari, and Edge. If you continue with this browser, you may see unexpected results.

The Faculty of Medicine - Biochemistry and Molecular Biology: Barshavit Zvi


 Last updated June 2021 - School of Pharmacy

List of Publications

(1) Bar-Shavit Z, Goldman R. Modulation of phagocyte activity by substance P and neurotensin. The Neuroendocrine Immune Network; 2018. p. 177-186.

(2) Krisher T, Bar-Shavit Z. Regulation of osteoclastogenesis by integrated signals from toll-like receptors. J Cell Biochem 2014;115(12):2146-2154.

(3) Aker M, Rouvinski A, Hashavia S, Ta-Shma A, Shaag A, Zenvirt S, et al. An SNX10 mutation causes malignant osteopetrosis of infancy. J Med Genet 2012;49(4):221-226.

(4) Bar-Shavit Z. Erratum: The osteoclast: A multinucleated, hematopoietic-origin, bone-resorbing osteoimmune cell(J Cell Biochem (2007) 102, (1130-1139)). J Cell Biochem 2008;104(5):1946-1947.

(5) Bar-Shavit Z. Taking a Toll on the bones: Regulation of bone metabolism by innate immune regulators. Autoimmunity 2008;41(3):195-203.

(6) Bar-Shavit Z. The osteoclast: A multinucleated, hematopoietic-origin, bone-resorbing osteoimmune cell. J Cell Biochem 2007;102(5):1130-1139.

(7) Amcheslavsky A, Bar-Shavit Z. Toll-like receptor 9 ligand blocks osteoclast differentiation through induction of phosphatase. J Bone Miner Res 2007;22(8):1301-1310.

(8) Aharon R, Bar-Shavit Z. Involvement of aquaporin 9 in osteoclast differentiation. J Biol Chem 2006;281(28):19305-19309.

(9) Amcheslavsky A, Bar-Shavit Z. Interleukin (IL)-12 mediates the anti-osteoclastogenic activity of CpG-oligodeoxynucleotides. J Cell Physiol 2006;207(1):244-250.

(10) Amcheslavsky A, Hemmi H, Akira S, Bar-Shavit Z. Differential contribution of osteoclast- and osteoblast-lineage cells to CpG-oligodeoxynucleotide (CpG-ODN) modulation of osteoclastogenesis. J Bone Miner Res 2005;20(9):1692-1699.

(11) Saltman LH, Javed A, Ribadeneyra J, Hussain S, Young DW, Osdoby P, et al. Organization of transcriptional regulatory machinery in osteoclast nuclei: Compartmentalization of Runx1. J Cell Physiol 2005;204(3):871-880.

(12) Zou W, Amcheslavsky A, Takeshita S, Drissi H, Bar-Shavit Z. TNF-α expression is transcriptionally regulated by RANK ligand. J Cell Physiol 2005;202(2):371-378.

(13) Amcheslavsky A, Zou W, Bar-Shavit Z. Toll-like receptor 9 regulates tumor necrosis factor-α expression by different mechanisms: Implications for osteoclastogenesis. J Biol Chem 2004;279(52):54039-54045.

(14) Zou W, Amcheslavsky A, Bar-Shavit Z. CpG oligodeoxynucleotides modulate the osteoclastogenic activity of osteoblasts via toll-like receptor 9. J Biol Chem 2003;278(19):16732-16740.

(15) Hakim I, Bar-Shavit Z. Modulation of TNF-α expression in bone marrow macrophages: Involvement of vitamin D response element. J Cell Biochem 2003;88(5):986-998.

(16) Zou WEI, Schwartz H, Endres S, Hartmann G, Bar-Shavit ZVI. CpG oligonucleotides: Novel regulators of osteoclast differentiation. FASEB J 2002;16(3):274-282.

(17) Zou W, Bar-Shavit Z. Dual modulation of osteoclast differentiation by lipopolysaccharide. J Bone Miner Res 2002;17(7):1211-1218.

(18) Zou W, Hakim I, Tschoep K, Endres S, Bar-Shavit Z. G protein β2 subunit antisense oligonucleotides inhibit cell proliferation and disorganize microtubule and mitotic spindle organization. J Cell Biochem 2001;83(1):136-146.

(19) Zou W, Hakim I, Tschoep K, Endres S, Bar-Shavit Z. Tumor necrosis factor-α mediates RANK ligand stimulation of osteoclast differentiation by an autocrine mechanism. J Cell Biochem 2001;83(1):70-83.

(20) Rosen H, Krichevsky A, Bar-Shavit Z. The enkephalinergic osteoblast. J Bone Miner Res 1998;13(10):1515-1520.

(21) Rosen H, Krichevsky A, Polakiewicz RD, Benzakine S, Bar-Shavit Z. Developmental regulation of proenkephalin gene expression in osteoblasts. Mol Endocrinol 1995;9(11):1621-1631.

(22) Abu-Amer Y, Bar-Shavit Z. Erratum: Regulation of TNF-α release from bone marrow-derived macrophages by vitamin D. (Journal of Cellular Biochemistry 55: (1994) (435-444). J Cell Biochem 1994;56(3):426.

(23) Abu-Amer Y, Bar-Shavit Z. Modulation of vitamin D increased H2O2 production and MAC-2 expression in the bone marrow-derived macrophages by estrogen. Calcif Tissue Int 1994;55(1):29-32.

(24) Rosen H, Bar‐Shavit Z. Dual role of osteoblastic proenkephalin derived peptides in skeletal tissues. J Cell Biochem 1994;55(3):334-339.

(25) Abu‐Amer Y, Bar‐Shavit Z. Regulation of TNF‐α release from bone marrow–derived macrophages by vitamin D. J Cell Biochem 1994;55(4):435-444.

(26) Abu-Amer Y, Bar-Shavit Z. Impaired bone marrow-derived macrophage differentiation in vitamin D deficiency. Cell Immunol 1993;151(2):356-368.

(27) Rosen H, Polakiewicz RD, Benzakine S, Bar-Shavit Z. Proenkephalin A in bone-derived cells. Proc Natl Acad Sci U S A 1991;88(9):3705-3709.

(28) Levi-Schaffer F, Bar-Shavit Z. Osteoblast-like cell line maintains in vitro rat peritoneal mast cell viability and functional activity. Immunology 1990;69(1):145-149.

(29) Gavison R, Bar-Shavit Z. Impaired macrophage activation in vitamin D3 deficiency: Differential in vitro effects of 1,25-dihydroxyvitamin D3 on mouse peritoneal macrophage functions. J Immunol 1989;143(11):3686-3690.

(30) Schlesinger M, Bar-Shavit Z, Hadar R, Rabinowitz R. Modulation of the expression of CD4 on HL-60 cells by exposure to 1,25-dihydroxyvitamin D3. Immunol Lett 1989;22(4):307-311.

(31) Stenson WF, Teitelbaum SL, Bar‐Shavit Z. Arachidonic acid metabolism by a vitamin D3‐differentiated human leukemic cell line. J Bone Miner Res 1988;3(5):561-571.

(32) Hruska KA, Bar-Shavit Z, Malone JD, Teitelbaum S. Ca2+ priming during vitamin D-induced monocytic differentiation of a human leukemia cell line. J Biol Chem 1988;263(31):16039-16044.

(33) Clohisy DR, Bar-Shavit Z, Chappel JC, Teitelbaum SL. 1,25-Dihydroxyvitamin D3 modulates bone marrow macrophage precursor proliferation and differentiation: Up-regulation of the mannose receptor. J Biol Chem 1987;262(33):15922-15929.

(34) Rodan SB, Imai Y, Thiede MA, Wesolowski G, Thompson D, Bar-Shavit Z, et al. Characterization of a Human Osteosarcoma Cell Line (Saos-2) with Osteoblastic Properties. Cancer Res 1987;47(18):4961-4966.

(35) Bar-Shavit Z, Horst RL, Chappel JC, Ross FP, Gray RW, Teitelbaum SL. 25-Hydroxyvitamin D3 metabolism in a human leukemia cell line. Calcif Tissue Int 1986;39(5):328-333.

(36) Bar-Shavit Z, Goldman R. Substance P and neurotensin. Methods Enzymol 1986;132(C):326-334.

(37) Welgus HG, Campbell EJ, Bar-Shavit Z. Human alveolar macrophages produce a fibroblast-like collagenase and collagenase inhibitor. Chest 1986;89(3 SUPPL.).

(38) Bar-Shavit Z, Kahn AJ, Stone KR, Trial J, Hilliard T, Reitsma PH, et al. Reversibility of vitamin D-induced human leukemia cell-line maturation. Endocrinology 1986;118(2):679-686.

(39) Bar-Shavit Z, Teitelbaum SL, Stricklin GP, Eisen AZ, Kahn AJ, Welgus HG. Differentiation of a human leukemia cell line and expression of collagenase inhibitor. Proc Natl Acad Sci U S A 1985;82(16):5380-5384.

(40) Welgus HG, Campbell EJ, Bar-Shavit Z, Senior RM, Teitelbaum SL. Human alveolar macrophages produce a fibroblast-like collagenase and collagenase inhibitor. J Clin Invest 1985;76(1):219-224.

(41) Key L, Carnes D, Cole S, Holtrop M, Bar-Shavit Z, Shapiro F, et al. Treatment of Congenital Osteopetrosis with High-Dose Calcitriol. New Engl J Med 1984;310(7):409-415.

(42) Bar-Shavit Z, Kahn AJ, Pegg LE. Glucocorticoids modulate macrophage surface oligosaccharides and their bone binding activity. J Clin Invest 1984;73(5):1277-1283.

(43) Teitelbaum SL, Bar-Shavit Z, Fallon MD, Imbimbo C, Malone JD, Kahn AJ. Glucocorticoids and bone resorption. Adv Exp Med Biol 1984;171:121-129.

(44) Reitsma PH, Rothberg PG, Astrin SM, Trial J, Bar-shavit Z, Hall A, et al. Regulation of myc gene expression in HL-60 leukaemia cells by a vitamin D metabolite. Nature 1983;306(5942):492-494.

(45) Goldman R, Bar-Shavit Z, Romeo D. Neurotensin modulates human neutrophil locomotion and phagocytic capability. FEBS Lett 1983;159(1-2):63-67.

(46) GOLDMAN R, BAR‐SHAVIT Z. On the Mechanism of the Augmentation of the Phagocytic Capability of Phagocytic Cells by Tuftsin, Substance P, Neurotensin, and Kentsin and the Interrelationship between Their Receptors. Ann New York Acad Sci 1983;419(1):143-155.

(47) Bar-Shavit Z, Teitelbaum SL, Kahn AJ. Saccharides mediate the attachment of rat macrophages to bone in vitro. J Clin Invest 1983;72(2):516-525.

(48) Bar-Shavit Z, Kahn AJ, Teitelbaum SL. Defective binding of macrophages to bone in rodent osteomalacia and vitamin D deficiency. In vitro evidence for a cellular defect and altered saccharides in the bone matrix. J Clin Invest 1983;72(2):526-534.

(49) Bar-Shavit Z, Goldman R. Tuftsin and substance P as modulators of phagocyte functions. Adv Exp Med Biol 1982;141:549-558.

(50) Bar-Shavit Z, Terry S, Blumberg S, Goldman R. Neurotensin - macrophage interaction: Specific binding and augmentation of phagocytosis. Neuropeptides 1982;2(6):325-335.

(51) Goldman R, Bar-Shavit Z, Shezen E, Terry S, Blumberg S. Enhancement of phagocytosis by neurotensin, a newly found biological activity of the neuropeptide. Adv Exp Med Biol 1982;155:133-141.

(52) Bar-Shavit Z, Noff D, Edelstein S, Meyer M, Shibolet S, Goldman R. 1,25-Dihydroxyvitamin D3 and the regulation of macrophage function. Calcif Tissue Int 1981;33(1):673-676.

(53) Bar-Shavit Z, Goldman R, Stabinsky Y. Enhancement of phagocytosis by substance P and its N-terminal tetrapeptide. Isr J Med Sci 1981;17(5):392.

(54) Bar-Shavit Z, Goldman R, Ofek I, Sharon N, Mirelman D. Mannose-binding activity of Escherichia coli: A determinant of attachment and ingestion of the bacteria by macrophages. Infect Immun 1980;29(2):417-424.

(55) Bar-Shavit Z, Goldman R, Stabinsky Y, Gottlieb P, Fridkin M, Teichberg VI, et al. Enhancement of phagocytosis - A newly found activity of Substance P residing in its N-terminal tetrapeptide sequence. Biochem Biophys Res Commun 1980;94(4):1445-1451.

(56) Mantovani A, Bar Shavit Z, Peri G, Polentarutti N, Bordignon C, Sessa C, et al. Natural cytotoxicity on tumour cells of human macrophages obtained from diverse anatomical sites. Clin Exp Immunol 1980;39(3):776-784.

(57) Bar-Shavit Z, Bursuker I, Goldman R. Functional tuftsin binding sites on macrophage-like tumor line P388DI and on bone marrow cells differentiated in vitro into mononuclear phagocytes. Mol Cell Biochem 1980;30(3):151-155.

(58) Stabinsky Y, Bar-Shavit Z, Fridkin M, Goldman R. On the mechanism of action of the phagocytosis-stimulating peptide tuftsin. Mol Cell Biochem 1980;30(2):71-77.

(59) Goldman R, Bar-Shavit Z, Raz A. Functional similarity and diversity in peritoneal macrophage populations induced in vivo by various stimuli. Adv Exp Med Biol 1979;121(A):323-332.

(60) Goldman R, Bar-Shavit Z, Bar-Shavit Z. Dual effect of normal and stimulated macrophages and their conditioned media on target cell proliferation. J Natl Cancer Inst 1979;63(4):1009-1016.

(61) Bar‐Shavit Z, Raz A, Goldman R. Complement and Fc receptor‐mediated phagocytosis of normal and stimulated mouse peritoneal macrophages. Eur J Immunol 1979;9(5):385-391.

(62) Bar‐Shavit Z, Stabinsky Y, Fridkin M, Goldman R. Tuftsin‐macrophage interaction: Specific binding and augmentation of phagocytosis. J Cell Physiol 1979;100(1):55-62.

(63) Bar-Shavit Z, Ofek I, Goldman R, Mirelman D, Sharon N. Mannose residues on phagocytes as receptors for the attachment of Escherichia coli and Salmonella typhi. Biochem Biophys Res Commun 1977;78(1):455-460.

(64) Bar-Shavit Z, Goldman R. Concanavalin A-mediated attachment and ingestion of yeast cells by macrophages. Exp Cell Res 1976;99(2):221-236.